US cancer survival hits 70% for the first time — 4.8 million deaths averted since 1991
Published · Researched 2026-09-22
What happened (dated facts)
On January 13, 2026, the American Cancer Society released Cancer Statistics, 2026 (published in CA: A Cancer Journal for Clinicians): for the first time, the five-year relative survival rate for all cancers combined reached 70% for people diagnosed during 2015–2021 in the United States — up from 50% in the mid-1970s and 63% in the mid-1990s. Survival gains since the mid-1990s are largest for historically fatal cancers: multiple myeloma (32% to 62%), liver cancer (7% to 22%), lung cancer (15% to 28%), and distant-stage disease overall (17% to 35%). The overall cancer mortality rate fell 34% from 1991 through 2023, averting an estimated 4.8 million deaths — driven by less smoking, earlier detection, and better treatment including immunotherapy and targeted therapy.
Why it is genuinely positive
Seven in ten Americans diagnosed with cancer now live five years or more — a number that has doubled since the mid-1990s. The gains are biggest where they matter most: the deadliest cancers, at the most advanced stages. This is the measurable payoff of decades of research funding, screening programs, and clinical trials — millions of people alive who would not have been.
Social pulse
Strong, celebratory circulation: upworthy Instagram post (Jan 15, 2026, 4,077 likes) — "If you had cancer in 1971, your odds of living longer than five years were just 50 percent. Today? It's 70 percent... Amazing what we can do when we fund, support, and prioritize science." Threads: cancer surgeon ajvictorymd (Jan 13, 2026) — "We didn't reach this milestone because of wellness trends. We reached it because of clinical trials (and the thousands of patients who participated), vaccines, and ea[rly detection]." Wide news coverage (ASCO Post, ScienceAlert, Morningstar/PR Newswire).
Verified quotes
- "Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s. This stunning victory is largely the result of decades of cancer research that provided clinicians with the tools to treat the disease more effectively, turning many cancers from a death sentence into a chronic disease." — Rebecca Siegel, senior scientific director of surveillance research at the American Cancer Society and lead author of the report (ACS press release, Jan 13, 2026).
Verification
- Tier: 1
- Primary source: American Cancer Society press release + Cancer Statistics, 2026 (Jan 13, 2026; pressroom.cancer.org). Proves: 70% five-year survival (2015–2021 diagnoses), 34% mortality decline since 1991, 4.8M deaths averted, per-cancer gains.
- Social sources: Instagram — upworthy (Jan 15, 2026, 4,077 likes, celebrating the milestone); Threads — ajvictorymd, cancer surgeon (Jan 13, 2026, crediting trials/vaccines/early detection). Proves: the milestone is circulating as good news on two social platforms with identifiable, non-sponsored voices.
- Positivity check: a genuine population-level milestone from the definitive annual source — with the honest caveats below. Passed.
Key facts
| Fact | Value | Source | Date |
|---|---|---|---|
| 5-year relative survival, all cancers | 70% (diagnosed 2015–2021) — first time | ACS press release | 2026-01-13 |
| Historical comparison | 50% mid-1970s; 63% mid-1990s | ACS / ASCO Post | 2026-01 |
| Myeloma survival | 32% → 62% since mid-1990s | ACS | 2026-01-13 |
| Liver cancer survival | 7% → 22% | ACS | 2026-01-13 |
| Lung cancer survival | 15% → 28% | ACS | 2026-01-13 |
| Distant-stage survival | 17% → 35% | ASCO Post | 2026-01 |
| Mortality decline | −34% since 1991; 4.8M deaths averted through 2023 | ACS | 2026-01-13 |
| Projected 2026 burden | ~2.11M new diagnoses; 626,140 deaths | ASCO Post | 2026-01 |
UNVERIFIED points
- Cancer remains the second-leading cause of death in the US; the report also flags adverse trends and areas where progress slowed — not detailed in this dossier.
- Proposed federal cancer-research funding cuts were flagged by ACS (Jan 2026) as a threat to continued progress — noted as context, not independently verified this session.